Proactiveinvestors USA & Canada Canntab Therapeutics Ltd https://www.proactiveinvestors.com Proactiveinvestors USA & Canada Canntab Therapeutics Ltd RSS feed en Sun, 21 Jul 2019 20:38:28 -0400 http://blogs.law.harvard.edu/tech/rss Genera CMS action@proactiveinvestors.com (Proactiveinvestors) action@proactiveinvestors.com (Proactiveinvestors) <![CDATA[Media files - Canntab Therapeutics hoping to bring their slow release tablet tech to U.S. ]]> https://www.proactiveinvestors.com/companies/stocktube/13592/canntab-therapeutics-hoping-to-bring-their-slow-release-tablet-tech-to-us-13592.html Tue, 04 Jun 2019 21:53:00 -0400 https://www.proactiveinvestors.com/companies/stocktube/13592/canntab-therapeutics-hoping-to-bring-their-slow-release-tablet-tech-to-us-13592.html <![CDATA[Media files - Canntab Therapeutics and Heritage Cannabis strike deal to work together ]]> https://www.proactiveinvestors.com/companies/stocktube/13552/canntab-therapeutics-and-heritage-cannabis-strike-deal-to-work-together-13552.html Fri, 31 May 2019 16:14:00 -0400 https://www.proactiveinvestors.com/companies/stocktube/13552/canntab-therapeutics-and-heritage-cannabis-strike-deal-to-work-together-13552.html <![CDATA[News - Buds & Duds: Cannabis stocks plummet, but Canntab bucks the trend as shares rise ]]> https://www.proactiveinvestors.com/companies/news/221327/buds--duds-cannabis-stocks-plummet-but-canntab-bucks-the-trend-as-shares-rise-221327.html Cannabis stocks saw sharp drops on Friday, with shares broadly down across US and Canadian markets.

The North American Marijuana Index, which tracks the top cannabis stocks in the US and Canada, was down 4.9% to 250.7 points by Friday's close. The Horizons Marijuana Life Sciences Index ETF sank 3.6% to C$18.62.

Buds

Despite the broad drops, a number of stocks lit up on Wednesday.

Canntab Therapeutics Ltd (CSE:PILL.CN) (OTCMKTS:CTABF) shares jumped Friday, a day after the firm announced it had inked a deal for capsule manufacturing with Heritage Cannabis Holdings Corp (CSE:CANN) (OTCQX: HERTF). 

Shares of Canntab jumped up 2.8% at C$0.73 in Toronto.

"After recently announcing the receipt of our cultivation licence for industrial hemp from Health Canada, we are immediately entering into important agreements to generate both short term and sustained revenue for the company," said Canntab's co-founder and CEO Jeff Renwick. "Our ability to encapsulate allows us to generate revenue without losing our long term focus on becoming the leading supplier of hard pill oral dose cannabinoid and terpene blends in the world."

Canntab is also known for its tablet technology, which includes an extended-release, instant-release, flash melt tablet and more. 

READ: Heritage Cannabis inks pact with Canntab Therapeutics for capsule manufacturing

Other gainers Wednesday included Cannabis One Holdings Inc (CSE:CBIS) (OTCMKTS:CAAOF), which announced earlier this week that a pair of vice presidents stepped into interim C-suite positions, effective immediately.

Shares were up 1.5% at C$1.38, up 4.9% at US$1.05 in New York.

Earlier this month, the firm announced it is expanding its multi-state footprint for both CBD and THC infused products with the leasing of two manufacturing and processing facilities located near Portland, Oregon.

Other gainers Friday included Golden Leaf Holdings Ltd (CSE:GLH) (OTCMKTS:GLDFF) which soared 5% at C$0.11 in Toronto.

The firm released its first quarter and annual 2018 financial results on Friday. For the year, revenue was up 43% US$16.3 million compared to US$11.5 million generated in 2017. It's first quarter revenue also saw strong gains. 

“We saw year-over-year revenue growth of 34% for the first quarter of 2019. We are pleased with the successful launch of two new brands in our Oregon and Nevada markets, Elysium Fields and Jackpot, showing strong customer support and trust," said CEO Karyn Barsa.

The company has cultivation, production and retail operations in Canada as well as in Oregon and Nevada.

Duds

There were a host of laggards on Friday, as the majority of cannabis stocks struggled.

MedMen Enterprises Inc (CSE:MMEN) (OTCQX:MMNFF) shares continued to drop Friday after the firm released its third-quarter earnings a day earlier, which didn’t meet analyst estimates. In particular, MedMen’s quarterly loss was higher than estimates.

Shares slipped 2% at US$2.98.

LA-based MedMen reported revenue of US$36.6 million, versus analyst expectations of US$49.2 million. It reported a net loss of US$63.1 million, reflecting a share loss of US$0.20. In the year-ago quarter, the loss stood at US$18.4 million.

READ: Green Growth Brands posts earnings highlighting the new company's rapid expansion throughout US

Other laggards Friday included Green Growth Brands (CSE:GGB) (OTCMKTS:GGBXF), which released its third-quarter earnings results. 

Shares were down 1.3% at C$3.70 in Canadian trading. 

The company posted a net loss for the period of US$15.1 million or $0.07 per share. For the period ending March 31, 2019, Green Growth Brands posted total revenues of US$5.6 million, largely driven by its Nevada operations, which contributed the bulk of sales.

It ended the quarter with US$5.4 million cash on hand. 

READ: Green Growth Brands posts earnings highlighting the new company's rapid expansion throughout US

Isodiol International (CSE:ISOL) (OTCMKTS:ISOLF) shares also dropped, down 8.9% at US$0.92 in New York and down 8.9% at C$1.23 by Friday's close on no news. The firm produces hemp derivatives in bulk quantities, white label formulas, and a branded line of finished goods.

Tilray Inc (NASDAQ:TLRY) shares also dropped on Friday down 2.8% at US$38.01 in New York.

Contact Katie Lewis at katie@proactiveinvestors.com

]]>
Fri, 31 May 2019 12:55:00 -0400 https://www.proactiveinvestors.com/companies/news/221327/buds--duds-cannabis-stocks-plummet-but-canntab-bucks-the-trend-as-shares-rise-221327.html
<![CDATA[News - Canntab Therapeutics inks pact with Heritage Cannabis for processing hemp for CBD-filled gelcaps ]]> https://www.proactiveinvestors.com/companies/news/221251/canntab-therapeutics-inks-pact-with-heritage-cannabis-for-processing-hemp-for-cbd-filled-gelcaps-221251.html Canntab Therapeutics Limited (CSE:PILL.CN) (OTCMKTS:CTABF) said Thursday that it has inked a pact with Heritage Cannabis Holdings Corp (CSE:CANN)(OTCQX:HERTF) for processing hemp for sale of CBD filled gel capsules.

Canntab has a Health Canada license to cultivate industrial hemp that it uses to extract cannabidiol (CBD) to manufacture cannabis pills.

According to the term sheet, Canntab will provide hemp to Heritage's subsidiary Purefarma Solutions for the purpose of processing that hemp into high quality CBD oil.

READ: Canntab Therapeutics fills a gap with its pioneering cannabis oral dosage products

The oil will then be turned into capsules by Canntab for Heritage, FSD Pharma Inc (CSE:HUGE), and other white labelling opportunities.

The agreement will begin immediately and is open-ended, non-exclusive and subject to a 120-day cancellation notice by either party.

Strategic deal to spur growth 

“This agreement with Canntab is a strategic fit for our growth as a contract service provider. It aligns with our vision to operate in final product verticals and advances our offering in the medical cannabis sector,” said Heritage Cannabis Holdings CEO Clint Sharples. “Purefarma’s extraction expertise and ability to provide quality oil is a good match for the high expectations that Canntab has for the products they will be bringing to market.”

Canntab's oral delivery system treats different ailments by delivering a uniform dosage of medicinal cannabis extract.

"After recently announcing the receipt of our cultivation licence for industrial hemp from Health Canada, we are immediately entering into important agreements to generate both short term and sustained revenue for the company,” said Canntab co-founder and CEO Jeff Renwick. “Our ability to encapsulate allows us to generate revenue without losing our long term focus on becoming the leading supplier of hard pill oral dose cannabinoid and terpene blends in the world."

Contact Uttara Choudhury at uttara@proactiveinvestors.com

Follow her on Twitter: @UttaraProactive 

]]>
Thu, 30 May 2019 14:06:00 -0400 https://www.proactiveinvestors.com/companies/news/221251/canntab-therapeutics-inks-pact-with-heritage-cannabis-for-processing-hemp-for-cbd-filled-gelcaps-221251.html
<![CDATA[Media files - Canntab Therapeutics wins Health Canada hemp cultivation license ]]> https://www.proactiveinvestors.com/companies/stocktube/13450/canntab-therapeutics-wins-health-canada-hemp-cultivation-license-13450.html Wed, 22 May 2019 16:41:00 -0400 https://www.proactiveinvestors.com/companies/stocktube/13450/canntab-therapeutics-wins-health-canada-hemp-cultivation-license-13450.html <![CDATA[Media files - Buds & Duds: Cannabis stocks climb; Canntab shares soar on hemp-cultivation licence ]]> https://www.proactiveinvestors.com/companies/stocktube/13431/buds--duds-cannabis-stocks-climb-canntab-shares-soar-on-hemp-cultivation-licence-13431.html Tue, 21 May 2019 16:29:00 -0400 https://www.proactiveinvestors.com/companies/stocktube/13431/buds--duds-cannabis-stocks-climb-canntab-shares-soar-on-hemp-cultivation-licence-13431.html <![CDATA[News - Buds & Duds: Cannabis stocks climb; Canntab shares soar on hemp-cultivation licence ]]> https://www.proactiveinvestors.com/companies/news/220722/buds--duds-cannabis-stocks-climb-canntab-shares-soar-on-hemp-cultivation-licence-220722.html Cannabis stocks went on a topsy-turvy ride Tuesday, with a mix of winners and losers across US and Canadian markets. 

The North American Marijuana Index, which tracks the top cannabis stocks in the US and Canada, was up 0.3% to 274.9 points on Tuesday. The Horizons Marijuana Life Sciences Index ETF was up 0.8% at C$20.19.

Buds

Canntab Therapeutics Ltd (CSE:PILL.CN) (OTCMKTS:CTABF) shares soared Tuesday after it announced it has received an industrial hemp cultivation licence from Health Canada in a major milestone for the cannabis company.

Shares of the firm were up 10% at C$0.77 in Canadian trading. 

The licence allows Canntab to cultivate industrial hemp. Canntab intends to use the licence to secure a large amount of hemp biomass that it will use to extract cannabidiol (CBD) to manufacture cannabis hard pills.

READ: Canntab Therapeutics hits new milestone with hemp-processing licence from Health Canada

PreveCeutical Medical Inc (CSE:PREV) (OTCMKTS:PRVCF) shares were on the rise Tuesday after it announced its research team has been approved to acquire human nasal tissue for the final phase of the cannabinoid-based, soluble gel, called Sol-gel. 

Shares of the company jumped 18.2% at C$0.07 in Canadian trading. 

Preveceutical said it believes that the outcomes of its Sol-gel program may be of value to companies with an interest in delivering cannabinoid/cannabis-based-derived pharmaceuticals to the central nervous system. 

READ: PreveCeutical Medical wins approval to acquire human tissue for final phase of Sol-gel technology testing

Other gainers Tuesday included Cronos Group Inc (NASDAQ:CRON) (TSE:CRON), which was up 5.8% at US$15.60 in New York, up 4.2% at C$20.91 in Toronto. 

Duds

The Supreme Cannabis Company Inc (TSE:FIRE) (OTCMKTS:SPRWF) shares nudged down on Tuesday, down 1.4% at US$1.41, up 1.4% at C$1.89 in Toronto.

On Friday, the firm announced plans to acquire Langley, BC-based producer BlissCo Cannabis Corp (CSE:BLIS) in an all-stock deal it valued at C$48 million.

Blissco has a 18,000 sq/ft production facility and produces cannabis oils. It received its production license in August 2018.

Shares of CBD manufacture Isodiol International Inc (CSE:ISOL) (OTCQB:ISOLF) dropped Tuesday, down 6.2% to US$0.77. The stock has struggled in recent weeks, on the back of challenges in Mexico, a result of changes by the Mexico’s Federal Commission for the Protection against Sanitary Risk (COFEPRIS) surrounding CBD regulation and licenses. 

 

Contact Katie Lewis at katie@proactiveinvestors.com

]]>
Tue, 21 May 2019 10:54:00 -0400 https://www.proactiveinvestors.com/companies/news/220722/buds--duds-cannabis-stocks-climb-canntab-shares-soar-on-hemp-cultivation-licence-220722.html
<![CDATA[Media files - Buds & Duds: Cannabis stocks flatten out; Canntab shares pop on OTCQX listing news ]]> https://www.proactiveinvestors.com/companies/stocktube/13180/buds--duds-cannabis-stocks-flatten-out-canntab-shares-pop-on-otcqx-listing-news-13180.html Wed, 01 May 2019 16:39:00 -0400 https://www.proactiveinvestors.com/companies/stocktube/13180/buds--duds-cannabis-stocks-flatten-out-canntab-shares-pop-on-otcqx-listing-news-13180.html <![CDATA[News - Buds & Duds: Cannabis stocks flatten out; Canntab shares pop on OTCQX listing news ]]> https://www.proactiveinvestors.com/companies/news/219498/buds--duds-cannabis-stocks-flatten-out-canntab-shares-pop-on-otcqx-listing-news-219498.html Cannabis stocks flattened out on Wednesday after steep declines on Tuesday. It's been a rocky week so far for cannabis stocks across broader North American markets. 

The North American Marijuana Index, which tracks the top cannabis stocks in the US and Canada, was flat at 297.7 points on Wednesday. The Horizons Marijuana Life Sciences Index ETF was up 0.4% at C$21.38.

Buds

Canntab Therapeutics Limited (CSE:PILL) (OTQX:CTABF) shares perked up on Wednesday after the OTC Markets Group Inc (OTCQX:OTCM) announced the company has qualified to trade on the best market, having been upgraded from the OTCQB venture.

Shares of Canntab were up 5.3% at C$0.80 in Toronto. The company specializes in the research and development of pharmaceutical-grade formulations of cannabinoids.

READ: Canntab Therapeutics to start trading on OTCQX best market

The company is the first to offer medical cannabis in pill form and its suite of products continues to grow. The tablets are intended to treat a variety of disorders including post-traumatic stress disorder and arthritis and can also act as a pain management and appetite loss drug for patients undergoing cancer treatments

"Historically, it's been difficult for US investors to take ownership of our company, that changes with our upgrade to the OTCQX best market,” said Canntab Therapeutics' chief financial officer Richard Goldstein in a statement. “This move also coincides with Canntab reaching a major milestone in April, which has opened the door for Canadian and international sales and white labeling."

WATCH: Canntab preparing for a busy summer after partner receives Health Canada License

Curaleaf Holdings (CSE:CURA) (OTCMKTS:CURLF) shares were on the rise -- big time -- on Wednesday as it announced it has inked a mammoth C$1.27 billion deal to buy the regulated cannabis business of Cura Partners Inc, a maker of oil for vape pens. Cura, based in Portland, Oregon, sells its Select brand marijuana products in more than 900 dispensaries. 

Shares soared 16.9% at C$15.55 in Canadian trading, up 16.8% at US$11.57 in New York. 

The significance of the deal is important: it marks the largest deal, based on a dollar figure (so far), between any US cannabis operator.

READ: The Green Organic Dutchman, Epican Medicinals win second retail licence to open another retail dispensary in Jamaica

The Green Organic Dutchman Holdings Ltd (TSX:TGOD) (OTCQX:TGODF) shares were cruising up Wednesday after it announced that it is opening its second legal cannabis retail store in Jamaica, along with Epican Medicinals. 

Shares were up 1.2% at US$3.39 in New York, up 1.1% at C$4.53 in Toronto. 

"Epican's Montego Bay store is a bright and well-designed space ideally located to serve local and visiting patients with Epican's locally produced premium organic cannabis," Green Organic Dutchman CEO Brian Athaide said in a statement.

"Our Kingston location witnessed increasing sales volumes; setting the stage for the grand opening of an Epican Herb House in Jamaica's largest tourist hub. It is an important milestone toward further expansion for Epican and TGOD in Jamaica."

Other gainers on Wednesday included Weekend Unlimited Inc (CSE:POT) (OTCMKTS:WKULF), which announced Wednesday that Chris Backus will be the interim president and CEO of the company.

Shares jumped 5.9% at C$0.09 in Canadian trading. 

Duds

A number of stocks declined on Wednesday. 

Sunniva Inc (CSE:SNN) (OTCQB:SNNVF) shares continued to slide on Wednesday after it released reported disappointing fiscal 2018 results earlier in the week. 

The company reported $18.8 million in revenue for the year-end period ending December 31, 2018, up from $16.1 million in 2017. Its net losses for 2018, however, rose to C$29 million versus C$17.5 million in The net loss for 2018 rose to $29 million versus last year’s $17.5 million, with the increase in net losses attributed to the company's growth in 2018, as its US operations in California expanded.

Markets responded, sending shares down 6% at US$3.30 in New York, down 4.9% at C$4.42 in Toronto.

TILT Holdings Inc (CSE:TILT) (OTCMKTS:SVVTF) shares dropped on Wednesday on no new news.

Shares were down 5% at C$2.65 in Toronto, down 5.3% at US$1.96 in New York.

Other laggards on Wednesday included CannTrust Holdings (OTCMKTS:CNTTF) (TSE:TRST) which slipped 5.6% at C$6.38 in New York, down 6.8% at C$8.56 in Toronto. 

Contact Katie Lewis at katie@proactiveinvestors.com

]]>
Wed, 01 May 2019 11:03:00 -0400 https://www.proactiveinvestors.com/companies/news/219498/buds--duds-cannabis-stocks-flatten-out-canntab-shares-pop-on-otcqx-listing-news-219498.html
<![CDATA[News - Canntab Therapeutics to start trading on OTCQX best market ]]> https://www.proactiveinvestors.com/companies/news/219480/canntab-therapeutics-to-start-trading-on-otcqx-best-market-219480.html The OTC Markets Group Inc (OTCQX: OTCM) announced Wednesday that Canntab Therapeutics Limited (CSE:PILL) (OTQX: CTABF), has qualified to trade on the best market,  having been upgraded from the OTCQB venture

Canntab Therapeutics, based in Markham, Ontario, specializes in the research and development of pharmaceutical-grade formulations of cannabinoids.

READ: Canntab Therapeutics fills a gap with its pioneering cannabis oral dosage products

"Canntab Therapeutics joins the OTCQX best market, trading alongside over 45 other cannabis companies that are innovators in the industry," said Jason Paltrowitz, executive vice president of corporate services at the OTC Markets Group. "Cross-trading on OTCQX provides Canntab Therapeutics' US investors with greater access to the company's financials, news and research reports. We look forward to supporting Canntab Therapeutics as it expands its footprint in the US."

Multiple patents

Canntab Therapeutics has 13 patents pending in the US and Canada. The company’s oral delivery system treats different ailments by delivering a uniform dosage of medicinal cannabis extract. This includes extended-release, flash melt, immediate release, modified release and bi-layered tablets.

The company is the first to offer medical cannabis in pill form and its suite of products continues to grow. The tablets are intended to treat a variety of disorders including post-traumatic stress disorder and arthritis and can also act as a pain management and appetite loss drug for patients undergoing cancer treatments

"Historically, it's been difficult for US investors to take ownership of our company, that changes with our upgrade to the OTCQX best market,” said Canntab Therapeutics' chief financial officer Richard Goldstein. “This move also coincides with Canntab reaching a major milestone in April, which has opened the door for Canadian and international sales and white labeling."

Hard pill oral dosage

Canntab's goal is to become a global leader of research in hard pill oral dosage therapeutic cannabis.

"Ultimately, this is another move along our strategic process with the goal of becoming the global leader of research in, production of and education about our advanced cannabinoid formulations that utilize our patent pending proprietary process," said Canntab Therapeutics CEO Jeff Renwick.

Contact Uttara Choudhury at uttara@proactiveinvestors.com

Follow her on Twitter: @UttaraProactive 

]]>
Wed, 01 May 2019 08:44:00 -0400 https://www.proactiveinvestors.com/companies/news/219480/canntab-therapeutics-to-start-trading-on-otcqx-best-market-219480.html
<![CDATA[Media files - Canntab preparing for a busy summer after partner receives Health Canada License ]]> https://www.proactiveinvestors.com/companies/stocktube/13084/canntab-preparing-for-a-busy-summer-after-partner-receives-health-canada-license-13084.html Wed, 24 Apr 2019 10:18:00 -0400 https://www.proactiveinvestors.com/companies/stocktube/13084/canntab-preparing-for-a-busy-summer-after-partner-receives-health-canada-license-13084.html <![CDATA[News - Canntab Therapeutics edges closer to revenue generation after FSD Pharma granted sales license ]]> https://www.proactiveinvestors.com/companies/news/218977/canntab-therapeutics-edges-closer-to-revenue-generation-after-fsd-pharma-granted-sales-license-218977.html Canntab Therapeutics Limited (CSE:PILL) (OTCMKTS:CTABF) edged closer to sales and revenue generation this week after its partner FSD Pharma Inc (CSE:HUGE) (OTCMKTS:FSDDF) received its sales license from Health Canada.

Canntab and FSD Pharma entered into a collaboration and profit sharing agreement in September 2018. Under the terms, FSD Pharma will assist Canntab to obtain a license to process and sell cannabis products and will provide Canntab with space at its facility in Cobourg, Ontario.

WATCH: Canntab Therapeutic agrees to deal with FSD Pharma and World Class Extractions

FSD’s new sales license allows Canntab to produce samples of CBD-containing capsules, which will enable the company to begin production and sales from its manufacturing space in FSD’s Cobourg facility.

Once the license is combined with an export permit, Canntab will be able to sell its products in foreign markets.

"We are thrilled that FSD has received its sales licence from Health Canada and want to congratulate the entire FSD team on this significant milestone,” said Jeffrey Renwick, CEO of Canntab.

The Toronto-based company will begin white labeling for Canadian licensed producers, including FSD, once it receives Health Canada approval for its capsules, it said in a statement.

Once FSD is able to export, Canntab will be able to sell its proposed products in foreign jurisdictions, including Australia and Mexico where existing agreements are already in place.

“We look forward to continuing to work closely with the team at FSD during this exciting new phase of our businesses,” said CEO Renwick.

READ: Canntab Therapeutics fills a gap with its pioneering cannabis oral dosage products

The company has 13 patents pending in the US and Canada. Canntab's oral delivery system treats different ailments by delivering a uniform dosage of medicinal cannabis extract. This includes extended-release, flash melt, immediate release, modified release and bi-layered tablets.

Canntab shares were trading around C$0.77 on Tuesday in Canada, and nearly 1% higher to US$0.60 on the OTC markets.

Contact Angela at angela@proactiveinvestors.com

Follow her on Twitter @AHarmantas

 

]]>
Tue, 23 Apr 2019 11:01:00 -0400 https://www.proactiveinvestors.com/companies/news/218977/canntab-therapeutics-edges-closer-to-revenue-generation-after-fsd-pharma-granted-sales-license-218977.html
<![CDATA[Media files - Canntab Therapeutic agrees to deal with FSD Pharma and World Class Extractions ]]> https://www.proactiveinvestors.com/companies/stocktube/12403/canntab-therapeutic-agrees-to-deal-with-fsd-pharma-and-world-class-extractions-12403.html Thu, 28 Feb 2019 16:50:00 -0500 https://www.proactiveinvestors.com/companies/stocktube/12403/canntab-therapeutic-agrees-to-deal-with-fsd-pharma-and-world-class-extractions-12403.html <![CDATA[News - Canntab Therapeutics fills a gap with its pioneering cannabis oral dosage products ]]> https://www.proactiveinvestors.com/companies/news/215553/canntab-therapeutics-fills-a-gap-with-its-pioneering-cannabis-oral-dosage-products-215553.html Canntab Therapeutics Ltd (CSE:PILL) (OTCMKTS: CTABF) is dedicated to the research and development of oral dosage therapeutic formulations of cannabis.

The Ontario-based company has 13 patents pending in the US and Canada. Canntab's oral delivery system treats different ailments by delivering a uniform dosage of medicinal cannabis extract. This includes extended-release, flash melt, immediate release, modified release and bi-layered tablets.

The company is the first to offer medical cannabis in pill form and its suite of products continues to grow. Canntab's goal is to become a global leader of research in, production of, and education about hard pill oral dosage therapeutic cannabis.

The tablets are intended to treat a variety of disorders including Post-Traumatic Stress Disorder and arthritis and can also act as a pain management and appetite loss drug for patients undergoing cancer treatments.

Canntab has also entered into a supply agreement with FSD Pharma and World Class Extractions to purchase hemp flower, which will be processed into gel capsules and tablets.

How is it doing?

The company has had a busy few months, with exciting things to come. 

Canntab recently signed a supply and loan agreement with FSD Pharma Inc, the licensed Canadian cannabis producer (CSE:HUGE), and extraction company World Class Extractions, to purchase hemp flower from Thomas Elcome. The trio will buy up to C$5 million of Thomas Elcome’s hemp crop for five years starting in 2019 at C$100 per kg per 1% of cannabidiol (CBD) extracted from the flower.

The three companies earlier struck a deal to buy about 1,000 kg of Thomas Elcome’s 2018 hemp crop.

The trio will process Elcome’s organic hemp flower crop into gel capsules and tablets at FSD’s facility in Cobourg, Ontario, which is currently being transformed into a large hydroponic indoor cannabis production and processing facility.

“This latest supply agreement will provide us with a significant amount of CBD oil over the next five years, which is required to manufacture our extensive suite of products for sale upon approval by Health Canada,” said Canntab Therapeutics CEO Jeffrey Renwick in a statement.

Canntab is in the process of building its own manufacturing facility, within the FSD Pharma plant, to produce cannabis oral dose delivery platforms. In the meantime, the company has converted another room (formerly known as grow room No. 6) into its interim facilities located within FSD’s Health Canada-approved facility, which through its wholly owned subsidiary FV Pharma Inc, has been issued a standard processing licence from Health Canada.

In other exciting news, the company has teamed up with a leading orthopedic surgeon at the University of British Columbia for a cannabis tablet trial aimed at reducing the need for opioids. Canntab plans to create the tablets for the study with FSD Pharma.

Led by Dr. Don Garbuz,  the randomized, double-blind, placebo-controlled clinical trial will test the effectiveness of the Canntab’s product in reducing the need for opioids after knee-replacement surgery. Needless to say, the uses could stretch much further than this, if successful. The University ethics approvals process is underway, with a decision expected shortly.

CFO says capsules will likely come first

“Right now, we’re just waiting to get the final go-ahead from Health Canada… We’d like to think that we could be in the market commercially, selling capsules at a minimum, by mid-year 2019,” says Canntab CFO, Richard Goldstein

Contact Katie Lewis at katie@proactiveinvestors.com

]]>
Thu, 28 Feb 2019 10:47:00 -0500 https://www.proactiveinvestors.com/companies/news/215553/canntab-therapeutics-fills-a-gap-with-its-pioneering-cannabis-oral-dosage-products-215553.html
<![CDATA[News - Canntab Therapeutics inks organic hemp supply and loan deal with FSD Pharma and World Class Extractions ]]> https://www.proactiveinvestors.com/companies/news/215539/canntab-therapeutics-inks-organic-hemp-supply-and-loan-deal-with-fsd-pharma-and-world-class-extractions-215539.html Canntab Therapeutics Limited (CSE:PILL) announced Thursday that it has entered into a supply and loan agreement with FSD Pharma Inc (CSE:HUGE) (OTCQB: FSDDF) and World Class Extractions Inc to purchase hemp flower from supplier Thomas Elcome who is the president of 10975443 Canada Inc.

According to the pact, the purchasers will have the right to buy up to C$5 million of the supplier’s hemp crop for five years starting in 2019 at C$100 per kg per 1% of Cannabidiol (CBD) extracted from the flower.

On February 12, Canntab said the three companies will buy 1,000 kg of Thomas Elcome’s 2018 hemp crop at a purchase price of $100,000 per kg per 1% of CBD extracted from the flower.

The trio will also process Elcome’s 2019-2024 organic hemp flower crop into gel capsules and tablets at FSD’s facility in Cobourg, Ontario, which is currently being transformed into a large hydroponic indoor cannabis production and processing facility.

The purchase price for the 2019 crop is pegged at C$1 million, not including taxes. Of this sum, C$500,000 will be paid by the purchasers as a loan to the supplier in the form of equipment to be paid back in the form of hemp.

“This latest supply agreement will provide us with a significant amount of CBD oil over the next five years, which is required to manufacture our extensive suite of products for sale upon approval by Health Canada,” said Canntab Therapeutics CEO Jeffrey Renwick in a statement.

READ: Canntab Therapeutics Ltd and FSD Pharma forge pact with World Class Extractions for hemp deal

The company is planning to conduct clinical trials with leading orthopaedic surgeon Dr Don Garbuz, as lead investigator to determine the potency of Canntab’s products in treating pain. The study will look at the use of Canntab tablets to treat pain after knee replacement surgery.

“This will include Canntab’s bi-layered hard pill consisting of both instant and extended release to be used in clinical trials to be conducted by Dr Garbuz, subject to approval by the University of British Columbia Research Ethics Board,” said Renwick.

Canntab Therapeutics, based in Markham, Ontario, specializes in the research and development of pharmaceutical-grade formulations of cannabinoids.

Meanwhile, FSD Pharma said it intended “to take full advantage” of the option to purchase the maximum amount of organic hemp from Elcome over the next five years starting with buying C$1 million of organic hemp in 2019.

“The hemp industry is expanding at an incredible rate and is expected to grow into a multi-billion dollar industry in North America,” said FSD Pharma interim CEO Dr Raza Bokhari. “Our processing license received last week, allows FSD to work with Canntab and World Class to process the hemp product into CBD oil, a significant saleable product that can be converted into gel capsules and tablets. Once the edibles legislation is in place later this year in Canada, FSD will be ready to process and supply the market.”

FSD Pharma is headquartered at the former Kraft plant in Cobourg, Ontario, about an hour's drive from Toronto, in a mammoth facility that sits on 72 acres of land, with 40 primed for development. The company is capitalizing on the need for indoor-grown, pharmaceutical-grade cannabis.

World Class Extractions CEO Michael McCombie, hailed the deal saying the company’s proprietary extraction technology is suited to process large hemp harvests into full spectrum oil. “We are preparing for the next stage of growth for our company as we await approval for our CSE listing,” McCombie.

“This supply and loan agreement signed with FSD, Canntab and World Class extends our relationship over several years,” said Thomas Elcome, president of 10975443 Canada Inc. “Our company looks forward to providing the highest-quality hemp.”

Contact Uttara Choudhury at uttara@proactiveinvestors.com

Follow her on Twitter: @UttaraProactive 

]]>
Thu, 28 Feb 2019 09:11:00 -0500 https://www.proactiveinvestors.com/companies/news/215539/canntab-therapeutics-inks-organic-hemp-supply-and-loan-deal-with-fsd-pharma-and-world-class-extractions-215539.html
<![CDATA[Media files - Canntab sign supply agreement with FSD Pharma and World Class Extractions ]]> https://www.proactiveinvestors.com/companies/stocktube/12212/canntab-sign-supply-agreement-with-fsd-pharma-and-world-class-extractions-12212.html Wed, 13 Feb 2019 12:42:00 -0500 https://www.proactiveinvestors.com/companies/stocktube/12212/canntab-sign-supply-agreement-with-fsd-pharma-and-world-class-extractions-12212.html <![CDATA[News - Canntab Therapeutics teams up with orthopedic surgeon for cannabis tablet trial ]]> https://www.proactiveinvestors.com/companies/news/210608/canntab-therapeutics-teams-up-with-orthopedic-surgeon-for-cannabis-tablet-trial-210608.html Canntab Therapeutics Ltd (CSE:PILL) (OTCMKTS:TLFTF) said Wednesday that it is teaming up with Dr Don Garbuz, an orthopedic surgeon, to study the effectiveness of the company’s Canntab tablets in reducing the need for opioids after knee-replacement surgery.

The Toronto-based company said in a press release that it’s seeking approval from the university to conduct a randomized, double-blind, placebo-controlled clinical trial, with Garbuz as lead investigator.

READ: Canntab Therapeutics wants to grow awareness of the cannabis group in Canada and elsewhere

Shares of Canntab climbed C$0.07 to C$1.12 in Wednesday's Canadian trading.

Garbuz is head of the division of lower limb reconstruction and oncology at the University of British Columbia’s division of orthopedics.

Canntab plans to create the tablets for the study with Toronto-based FSD Pharma Inc (OTCMKTS:FSDDF), a licensed producer under the Access to Cannabis for Medical Purposes Regulations.

“This study will help advance our understanding of the potential effects of cannabis as a treatment for pain and will become the basis for conducting future cannabinoid and pain management clinical trials," Garbuz said in a statement. "This important study aims to help us better understand the potential impact of cannabis as an alternative for opioids, so that patients might face better outcomes."

It’s not unusual for patients to misuse opioids after surgery, with nearly 5% of “previously opiate-naive patients” becoming chronic abusers, Canntab said in the press release.

The total cost of the study is estimated at C$600,000, with an anticipated time frame of 12 to 18 months.

 

Contact Dennis Fitzgerald at dennis@proactiveinvestors.com

]]>
Wed, 05 Dec 2018 10:51:00 -0500 https://www.proactiveinvestors.com/companies/news/210608/canntab-therapeutics-teams-up-with-orthopedic-surgeon-for-cannabis-tablet-trial-210608.html
<![CDATA[News - Canntab Therapeutics applies with Health Canada to become a licensed cannabis producer ]]> https://www.proactiveinvestors.com/companies/news/209214/canntab-therapeutics-applies-with-health-canada-to-become-a-licensed-cannabis-producer-209214.html Canntab Therapeutics Ltd (CSE:PILL) has submitted an application with Health Canada to become a licensed producer (non-grower) under the Access to Cannabis for Medical Purposes Regulations.

The Markham, Ontario, company also said it reached a milestone in its development of a patent-pending oral extended-release formulation for cannabinoids in collaboration with Emblem Corp (TSXV:EMC) (OTCQX:EMMBF).

Dissolution testing indicated that the extended-release tablets released cannabinoids consistently over a 12-hour period. Given these positive test results, Canntab is manufacturing batches of these tablets for further clinical testing. This will lead to the filing of dossiers with regulatory agencies around the world for approval of Canntab’s oral dose delivery systems.

“In our short history on the public markets, Canntab has already reached a number of significant milestones," said Canntab CEO Jeff Renwick.

The company also pointed to Health Canada’s approval of its 420 Therapeutics brand of cannabis wellness products, which are made with purified organic hemp seed oil. Canntab said it is an important step toward manufacturing full spectrum hemp-derived cannabinoid, or CBD.

BIG PICTURE: Canntab Therapeutics merging medical cannabis with pharmaceutical expertise

Canntab also said it has signed a non-binding letter of intent with NewCanna SA of Bogota, Colombia, for the establishment of a bilateral relationship covering the sale and distribution of Canntab’s products in Colombia, Chile, Paraguay and Spain with a one-time, non-refundable license fee of $2 million payable to Canntab by NewCanna.

The company also signed a non-binding LOI with Labsco Promedic SA to establish a joint venture covering sales and distribution of Canntab products in Mexico.

"Canntab is leveraging its first mover advantage and developing an important IP portfolio to actively pursue other high-level discussions for partnerships with industry leaders. CBD and THC in tablet form is an important category with few worldwide players at this time and Canntab believes that it is well positioned to build significant shareholder value by aggressively pursuing these opportunities,” Renwick said.

 

Contact Rene Pastor at rene.pastor@proactiveinvestors.com

]]>
Wed, 14 Nov 2018 11:38:00 -0500 https://www.proactiveinvestors.com/companies/news/209214/canntab-therapeutics-applies-with-health-canada-to-become-a-licensed-cannabis-producer-209214.html
<![CDATA[Media files - Canntab Therapeutics signs deal to enter medicinal cannabis market in Mexico ]]> https://www.proactiveinvestors.com/companies/stocktube/11087/canntab-therapeutics-signs-deal-to-enter-medicinal-cannabis-market-in-mexico-11087.html Thu, 01 Nov 2018 16:25:00 -0400 https://www.proactiveinvestors.com/companies/stocktube/11087/canntab-therapeutics-signs-deal-to-enter-medicinal-cannabis-market-in-mexico-11087.html <![CDATA[News - Canntab Therapeutics shares higher as pot pill firm enters Mexico market ]]> https://www.proactiveinvestors.com/companies/news/208249/canntab-therapeutics-shares-higher-as-pot-pill-firm-enters-mexico-market-208249.html Pot-pill developer Canntab Therapeutics Limited (CSE:PILL) told investors it was to enter the medicinal cannabis market in Mexico, sending shares higher.

The company on Wednesday said it had inked a non-binding Letter of Intent (LOI) with Labsco Promedic SA de CV of Monterrey, Mexico over a joint venture for an initial period of five years.

Among the agreements, Labsco shall be responsible for funding and obtaining any regulatory, licencing or other such approvals for importing and distributing Canntab products in Mexico and shall provide physical premises.

Meanwhile, Canntab shall license current patents and know-how, subject to completion of a license agreement.

Canntab will also produce products in bulk from its Canadian facilities, and shall provide products to the joint venture at an agreed price and margin.

"Following several months of discussion including introductory due diligence, we are pleased to welcome Labsco and their team to the Canntab family," said Jeff Renwick, chief executive at Canntab.

"We are excited about the potential for our sustained release tablet formulations of cannabinoids in the Mexican market.

"Following our recently announced application to Health Canada to become a Licenced Producer under the ACMPR, and along with our production facility in collaboration with FSD Pharma, Canntab is building a significant international distribution network for its products. Labsco is the newest addition to this developing line of business for Canntab".

It is worth noting that the letter of intent is subject to completion of a definitive agreement.

Canntab said it expects anticipates to complete the formal agreement before the end of the year.

The firm's shares added just over 8% in Toronto to stand at $1.30 each.

]]>
Wed, 31 Oct 2018 10:10:00 -0400 https://www.proactiveinvestors.com/companies/news/208249/canntab-therapeutics-shares-higher-as-pot-pill-firm-enters-mexico-market-208249.html
<![CDATA[News - Canntab Therapeutics files to become licensed producer under medical purposes regulations ]]> https://www.proactiveinvestors.com/companies/news/207496/canntab-therapeutics-files-to-become-licensed-producer-under-medical-purposes-regulations-207496.html Pot-pill developer Canntab Therapeutics Limited (CSE:PILL) says its application to become a licensed producer under the  Access to Cannabis for Medical Purposes Regulations (ACMPR) has been received by Health Canada.

The license, if granted, would allow the company to process cannabis products at its current production facility in Ontario with minimal additional capital expenditures compared to a new purpose-built facility.

"We are excited to announce, as we enter into a new era of legalization, that Canntab has submitted its application to Health Canada to become a licensed producer," said Jeff Renwick, the CEO and director of Canntab.

"This is another step that enables Canntab to further diversify its manufacturing and distribution capabilities towards a worldwide rollout of its suite of precision oral dose delivery platforms for cannabis-based products," he added.

Colombian tie up

Earlier this month, the company announced a new tie-up with Colombian group NewCanna SAS, which will allow it to sell the former's products in Colombia, Chile, Paraguay and Spain.

The letter of intent (LOI) will grant NewCanna the right to sell and distribute certain of Canntab's exclusive proprietary products, and the right to use its knowledge and patents.

"We welcome this key development in our business plan and the opportunity to rapidly expand into the many potential markets for Canntab products worldwide," Renwick had said.

"The wide variety of NewCanna's cannabis strains will give us access to a full range of Cannabinoids and terpenoids to further our development pipeline.

"In conjunction with, our recently announced relationship with FSD Pharma and with our progressing work with Emblem Cannabis Corporation, I believe Canntab is poised to be the world leader in pharmaceutical grade, standardized tablet dosage of medicinal cannabis."

Canntab Therapeutics shares eased  1.75% to stand at $1.68 each.

]]>
Fri, 19 Oct 2018 10:54:00 -0400 https://www.proactiveinvestors.com/companies/news/207496/canntab-therapeutics-files-to-become-licensed-producer-under-medical-purposes-regulations-207496.html
<![CDATA[Media files - Canntab Therapeutics signs deal giving them access to South America and Spain ]]> https://www.proactiveinvestors.com/companies/stocktube/10682/canntab-therapeutics-signs-deal-giving-them-access-to-south-america-and-spain-10682.html Mon, 01 Oct 2018 14:10:00 -0400 https://www.proactiveinvestors.com/companies/stocktube/10682/canntab-therapeutics-signs-deal-giving-them-access-to-south-america-and-spain-10682.html <![CDATA[News - Canntab Therapeutics strikes distribution and supply deal with Colombian group NewCanna ]]> https://www.proactiveinvestors.com/companies/news/206102/canntab-therapeutics-strikes-distribution-and-supply-deal-with-colombian-group-newcanna-206102.html Pot-pill developer Canntab Therapeutics Limited (CSE:PILL) has announced a new tie-up with Colombian group NewCanna SAS, which will allow it to sell the former's products in Colombia, Chile, Paraguay and Spain.

The letter of intent (LOI) will grant NewCanna the right to sell and distribute certain of Canntab's exclusive proprietary products, and the right to use its knowledge and patents.

"We welcome this key development in our business plan and the opportunity to rapidly expand into the many potential markets for Canntab products worldwide," said Jeff Renwick, Canntab's chief executive.

Wide variety

"The wide variety of NewCanna's cannabis strains will give us access to a full range of Cannabinoids and terpenoids to further our development pipeline.

"In conjunction with, our recently announced relationship with FSD Pharma and with our progressing work with Emblem Cannabis Corporation, I believe Canntab is poised to be the world leader in pharmaceutical grade, standardized tablet dosage of medicinal cannabis."

The deal provides for a five- year distribution agreement for Canntab's oral sustained release tablet formulations in the countries above.

It also allows for the supply of up to US$10 million of NewCanna cannabis oil to Canntab for which Canntab will place a deposit of US$1mln.

The parties have 60 days to seal the deal, after which a non-refundable license fee of $2 million will be payable to Canntab by NewCanna in consideration for the exclusive license to be granted by Canntab to NewCanna.

Oil exportation licence

NewCanna holds an oil-exportation licence and has access to, or control over, four cultivation and extraction licenses. It also has four additional licenses under application and over 3,000 hectares of cannabis production.

"When carefully building a global network of cultivators and distribution channels in today's fast-growing medicinal cannabis market it is imperative to identify the best possible pharma-grade manufacturing partners, this is why, after rigorously evaluating many other possible alliances, we have decided Canntab has the vision, infrastructure and knowledge that represents our best interest moving forward," said Santiago Londono, founder and chief executive of New Canna.

"Our main goal is to deliver the most responsible and precise dosage to every patient that trusts our brands, and we believe Canntab will be instrumental in achieving this objective."

Shares in Toronto added over 9% to $1.89.

]]>
Mon, 01 Oct 2018 08:43:00 -0400 https://www.proactiveinvestors.com/companies/news/206102/canntab-therapeutics-strikes-distribution-and-supply-deal-with-colombian-group-newcanna-206102.html
<![CDATA[News - Canntab Therapeutics poised to start pill production at FSD Ontario facility as it delivers manufacturing equipment ]]> https://www.proactiveinvestors.com/companies/news/205663/canntab-therapeutics-poised-to-start-pill-production-at-fsd-ontario-facility-as-it-delivers-manufacturing-equipment-205663.html Cannabis pill focused developer Canntab Therapeutics Limited (CSE:PILL) unveiled progress Tuesday on its profit-sharing collaboration with medical pot producer FSD Pharma Inc (CSE:HUGE).

FSD has received its first delivery of manufacturing equipment at its Cobourg plant in Ontario from Canntab, it told investors.

FSD thrilled

"We are thrilled that Canntab is moving so quickly to set up its manufacturing facility at our company," said Zeeshan Saeed, EVP (executive vice president) and director of FSD Pharma.

As revealed in July this year, under the letter of intent (LOI) FSD Pharma will help Canntab to obtain a license to process and sell cannabis products under the new legislation in  Canada to legalise it.

It will also provide up to 10,000 sq ft of space at its 620,000  sq ft facility in Ontario.

The manufacturing equipment delivered consists of a high output tablet press capable of pressing more than 1.5 million tablets per day, as well as blending machinery, large-scale process and drying equipment and packaging equipment.

Canntab will build and install its own manufacturing facility to produce novel cannabis oral dose delivery platforms, including gel capsules and tablets.

"With this first delivery of manufacturing equipment at the Cobourg plant, we can begin the process of setting up our manufacturing space in collaboration with FSD Pharma," said Jeffrey Renwick, chief executive at Canntab, on Tuesday.

"We expect manufacturing of our suite of novel cannabis oral dose delivery platforms, including gel capsules and tablets to begin in earnest."

Tremendous opportunity

FSD Pharma and Canntab see "tremendous opportunity" in offering pharmaceutical quality cannabis-based tablets, as many doctors are averse to prescribing smoked cannabis as a solution to patients' health concerns, Canntab said.

Under the plan, Canntab will hand FSD  50% of the profits that Canntab receives on any retail sales of Canntab products through channels that are established by FSD Pharma.

Meanwhile, FSD will be entitled to retain 50% of the profits on FSD Pharma's sales of the Canntab products.

Canntab will also pay FSD a royalty of 3.5% of Canntab's sale price for all Canntab products that are manufactured and sold from the Canntab premises.

]]>
Tue, 25 Sep 2018 10:08:00 -0400 https://www.proactiveinvestors.com/companies/news/205663/canntab-therapeutics-poised-to-start-pill-production-at-fsd-ontario-facility-as-it-delivers-manufacturing-equipment-205663.html
<![CDATA[News - Canntab Therapeutics reports record share price highs in wake of corporate advances ]]> https://www.proactiveinvestors.com/companies/news/205370/canntab-therapeutics-reports-record-share-price-highs-in-wake-of-corporate-advances-205370.html Pot pill developer Canntab Therapeutics Limited (CSE:PILL) pointed out the highs reached by its share price Wednesday in the wake of news announcements.

In a release Thursday, the firm said its shares had reached a new all-time daily high and closing prices of C$1.74 and C$1.41, respectively, on the Canadian Securities Exchange (CSE).

The company also traded an aggregate of 1.6mln shares Wednesday at a value of C$2.06mln, which represents its all-time high daily volume and surpasses its previous high set on its first day of public trading on April 20.

“We are thrilled that the investment community is taking notice of the positive developments occurring at Canntab,” said Canntab CEO Jeff Renwick in a statement.

Shares in Canntab surged this week after the company unveiled positive test results on its oral extended release formulation.

Read: Canntab Therapeutics shares reach all-time highs amid flurry of announcements

The firm said it would now begin manufacturing batches of these tablets for pharmacokinetic and clinical testing.

The testing was a collaboration with medical cannabis producer Emblem Crop (CVE:EMC, OTCQX:EMMBF) and showed that the pills released cannabinoids consistently over a 12-hour period.

Also this week, Canntab's plans to provide pot pills to patients and doctors in Canada were further advanced, as the company struck a definitive collaboration and profit sharing agreement with FSD Pharma.

As previously reported, the latter will help the firm to obtain a license to process and sell cannabis products and will provide it with up to 10,000 square feet at its facility, which lies one hour east of Toronto in Cobourg, Ontario.

Based in Markham, Ontario, Canntab is engaged in the research and development of advanced pharmaceutical grade formulations of cannabinoids. Canntab has developed in-house technology to deliver standardized medical cannabis extract from selective strains in a variety of extended or sustained release pharmaceutical dosages for therapeutic use.

Canntab shares jumped 17.7% to C$1.66 in Thursday’s afternoon session.

]]>
Thu, 20 Sep 2018 14:11:00 -0400 https://www.proactiveinvestors.com/companies/news/205370/canntab-therapeutics-reports-record-share-price-highs-in-wake-of-corporate-advances-205370.html
<![CDATA[News - Canntab Therapeutics shares reach all-time highs amid flurry of announcements ]]> https://www.proactiveinvestors.com/companies/news/205246/canntab-therapeutics-shares-reach-all-time-highs-amid-flurry-of-announcements-205246.html Pot pill developer Canntab Therapeutics Ltd (CSE:PILL) noted the highs reached by its share price Tuesday following news announcements.

In a stock market release Wednesday, the firm said that its shares had reached a new all-time daily high and closing prices of C$1.25 and C$1.22, respectively, on the Canadian Securities Exchange (CSE).

READ: Canntab Therapeutics shares light up as it sees positive test results on its extended release tablets

That represents a 25% and 22% premium on the price of the shares that were issued in the private placing that closed concurrently with its reverse takeover in April, it noted.

And today, the stock built on gains those gains, adding 16.39% to stand at C$1.43.

"We are proud to report that Canntab is executing on its promise to deliver value and liquidity to our shareholders," said Jeff Renwick, the chief executive and director of Canntab.

"Today's closing price demonstrates that the marketplace believes in our vision, and we intend to continue to reach new highs," he added.

Yesterday, shares surged as Canntab unveiled positive test results on its oral extended release formulation.

WATCH: Canntab Therapeutics calling their extended release tablet a "game changer"

The firm said it would now begin manufacturing batches of these tablets for pharmacokinetic and clinical testing.

The testing was a collaboration with medical cannabis producer Emblem Corp (CVE:EMC, OTCQX: EMMBF) and showed that the pills released cannabinoids consistently over a 12-hour period.

Also yesterday, Canntab's plans to provide pot pills to patients and doctors in Canada was further advanced - as the company struck a definitive collaboration and profit sharing agreement with FSD Pharma.

As previously reported, the latter will help the firm to obtain a license to process and sell cannabis products and will provide it with up to 10,000 square feet at its facility, which lies one hour east of Toronto in Cobourg, Ontario.

]]>
Wed, 19 Sep 2018 10:05:00 -0400 https://www.proactiveinvestors.com/companies/news/205246/canntab-therapeutics-shares-reach-all-time-highs-amid-flurry-of-announcements-205246.html
<![CDATA[Media files - Canntab Therapeutics calling their extended release tablet a "game changer" ]]> https://www.proactiveinvestors.com/companies/stocktube/10519/canntab-therapeutics-calling-their-extended-release-tablet-a-game-changer--10519.html Tue, 18 Sep 2018 15:45:00 -0400 https://www.proactiveinvestors.com/companies/stocktube/10519/canntab-therapeutics-calling-their-extended-release-tablet-a-game-changer--10519.html <![CDATA[News - Canntab Therapeutics shares light up as it sees positive test results on its extended release tablets ]]> https://www.proactiveinvestors.com/companies/news/205149/canntab-therapeutics-shares-light-up-as-it-sees-positive-test-results-on-its-extended-release-tablets-205149.html Pot pill developer Canntab Therapeutics Ltd (CSE:PILL) saw shares surge in Toronto Tuesday as it unveiled positive test results on its oral extended release formulation.

Given this, Canntab said it will now begin manufacturing batches of these tablets for pharmacokinetic and clinical testing.

The test work was a collaboration with medical cannabis producer Emblem Corp (CVE:EMC, OTCQX: EMMBF) and showed that the pills released cannabinoids consistently over a 12-hour period.

"Achieving this milestone marks a key step in the development of the oral extended release formulation," said John H. Stewart, the president at Emblem Medical.

"The production of a reliable, long-acting formulation is complex and often very difficult to achieve. The results of the dissolution study signal that we will proceeding to the next stages of the product's development with Canntab."

Milestone payment

Under the agreement between the pair, as part of this achievement, Emblem has made the required milestone payment to Canntab.

Also today, Canntab's plans to provide pot pills to patients and doctors in  Canada was advanced further - as it struck a definitive collaboration and profit sharing agreement with FSD Pharma.

As previously stated, the latter will help the firm to obtain a license to process and sell cannabis products and will provide it with up to 10,000 square feet at its facility, which lies one hour east of Toronto in Cobourg, Ontario.

Own manufacturing facility

Canntab will build and install, at its expense, its own manufacturing facility within the larger FSD premises.

It will produce a suite of novel oral dose delivery platforms, including gel capsules and tablets, and other types of cannabis-based products, including sleep aids and pain relievers.

It is planned that the premises will be used to supply Canadian and International markets such as Australia and Germany, which legally allow cannabis.

"Now that our definitive agreement is signed with FSD Pharma, we intend to work with the Company to move our application through the Health Canada process as swiftly and smoothly as possible, said Jeffrey Renwick, chief executive of Canntab.

Under the plan, Canntab will hand FSD  50% of the profits that Canntab receives on any retail sales of Canntab products through channels that are established by FSD Pharma.

Meanwhile, FSD will be entitled to retain 50% of the profits on FSD Pharma's sales of the Canntab products.

Canntab will also pay FSD a royalty of 3.5% of Canntab's sale price for all Canntab Products that are manufactured and sold from the Canntab Premises

Canntab shares shot up 20% in Toronto to stand at C$1.20.

]]>
Tue, 18 Sep 2018 10:01:00 -0400 https://www.proactiveinvestors.com/companies/news/205149/canntab-therapeutics-shares-light-up-as-it-sees-positive-test-results-on-its-extended-release-tablets-205149.html
<![CDATA[News - Canntab Therapeutics wants to grow awareness of the cannabis group - in Canada and elsewhere ]]> https://www.proactiveinvestors.com/companies/news/204653/canntab-therapeutics-wants-to-grow-awareness-of-the-cannabis-group-in-canada-and-elsewhere-204653.html Cannabis-pill firm Canntab Therapeutics Ltd (CSE:PILL) is launching a new communications strategy and has hired Mackie Research as financial advisor and Hybrid Financial Ltd to assist with investor relations.

In a regulatory release, the company reminded investors that it listed on the Canadian Securities Exchange in April this year.

"Management is pleased with the company's operational progress since its public listing and feels that it is time to turn a greater attention to growing awareness of the company, its activities and the unique business opportunities being developed in the medicinal cannabis markets, and potentially in the recreational cannabis markets — both in Canada and Internationally," it said.

The business plan has focused on receiving Health Canada approval for research and development (R&D) on oral sustained release formulations of Canntab's cannabinoids products, which it achieved in May.

It also filed new patent applications related to its intellectual property (IP) portfolio.

In July, it also announced a profit-sharing collaboration with medical pot producer FSD Pharma Inc.

Under the letter of intent (LOI), FSD Pharma will help Canntab to obtain a license to process and sell cannabis products under the new legislation.

Canntab will pay a monthly, non-refundable work fee of C$20,000 to Mackie Research and grant 200,000 options to the group.

It will also pay a monthly fee of $14,000 to Hybrid; and grant 250,000 options to Hybrid.

Shares in Canntab were unchanged at C$1.02.

]]>
Tue, 11 Sep 2018 10:02:00 -0400 https://www.proactiveinvestors.com/companies/news/204653/canntab-therapeutics-wants-to-grow-awareness-of-the-cannabis-group-in-canada-and-elsewhere-204653.html
<![CDATA[Media files - Canntab Therapeutics building cannabis delivery facility with FSD Pharma ]]> https://www.proactiveinvestors.com/companies/stocktube/9911/canntab-therapeutics-building-cannabis-delivery-facility-with-fsd-pharma-9911.html Thu, 19 Jul 2018 12:33:00 -0400 https://www.proactiveinvestors.com/companies/stocktube/9911/canntab-therapeutics-building-cannabis-delivery-facility-with-fsd-pharma-9911.html <![CDATA[News - A 'godfather' of the cannabis industry Lorne Gertner joins Canntab Therapeutics as consultant ]]> https://www.proactiveinvestors.com/companies/news/200866/a-godfather-of-the-cannabis-industry-lorne-gertner-joins-canntab-therapeutics-as-consultant-200866.html Cannabis pill firm Canntab Therapeutics Ltd (CSE:PILL) revealed that one of the 'godfathers of the industry' and a serial entrepreneur Lorne Gertner has become a  strategic consultant to the company.

"Mr Gertner has significant experience on the boards of a number of publicly traded cannabis companies, including Hiku Brands Company, and has developed a global network of contacts in the cannabis industry along with a deep understanding of retail distribution, both of which Canntab hopes to leverage as it positions itself for expansion into international markets," the firm said in a regulatory statement.

Canntab has developed in-house technology to deliver standardised medical cannabis extract from selective strains.

Last month, it launched the first of its '420 Therapeutics' brand of Cannabis wellness products - Hemp oil gel capsules. Each capsule contains 50mg of purified hemp seed oil extracted from cannabis sativa and suspended in coconut oil. Hemp oil is supposed to have health benefits.

Gertner said..: "... I believe the ultimate solution to the delivery of Cannabis will be through a hard pill.

"The problem with edibles today or infusion of any type is that they are combined with excessive sugar, and sugar is one of the killers in our society today.

"People today want something natural and our (Canntab) intention is to deliver a whole plant medicine through a hard tablet that is fast acting and long lasting."

 Canntab finance chief Richard Goldstein said of Gertner: "He has been an advocate for medicinal cannabis use, and even supported a group of patients that had to face legal ramifications for using cannabis.

"He understood the benefits of medicinal cannabis long before it was permitted. He is a visionary and has developed a global network, which will allow Canntab in developing new business opportunities."

Gertner will receive 100,000 incentive stock options, each entitling the holder to acquire one share for three years at C$1.00 per share.

]]>
Mon, 16 Jul 2018 09:20:00 -0400 https://www.proactiveinvestors.com/companies/news/200866/a-godfather-of-the-cannabis-industry-lorne-gertner-joins-canntab-therapeutics-as-consultant-200866.html
<![CDATA[News - Canntab Therapeutics unveils collaboration with FSD Pharma ahead of Canada's nationwide legalization ]]> https://www.proactiveinvestors.com/companies/news/200490/canntab-therapeutics-unveils-collaboration-with-fsd-pharma-ahead-of-canada-s-nationwide-legalization-200490.html Canntab Therapeutics Ltd (CSE:PILL) is lining up its ducks ahead of the legalization of cannabis in Canada on October 17 this year - as it announced a profit sharing collaboration with medical pot producer FSD Pharma Inc.

Under the letter of intent (LOI) FSD Pharma will help Canntab to obtain a license to process and sell cannabis products under the new legislation.

It will also provide up to 10,000 sq ft of space at its 620,000  sq ft facility, which lies one hour east of Toronto in Cobourg, Ontario.

There, Canntab will build and install its own manufacturing facility to produce novel cannabis oral dose delivery platforms, including gel capsules and tablets.

"We are thrilled to announce our partnership with FSD Pharma, which not only provides us with space at their world class facility in Cobourg, but also gives us access to their deep knowledge base, which we believe will help us move our application through the Health Canada process as quickly and smoothly as possible," said Jeffrey Renwick, Canntab chief executive.

"With this partnership in place, we believe that Canntab is well-position to capitalize on the impending legalization of cannabis on October 17, 2018".

Under the plan, Canntab will hand FSD  50% of the profits that Canntab receives on any retail sales of Canntab products through channels that are established by FSD Pharma.

Meanwhile, FSD will be entitled to retain 50% of the profits on FSD Pharma's sales of the Canntab Products.

Canntab will also pay FSD a royalty of 3.5% of Canntab's sale price for all Canntab Products that are manufactured and sold from the Canntab Premises.

"This could be HUGE," said Thomas Fairfull, chief executive at FSD Pharma.

"Pills and tablets are the norm for most patients' method of consuming medicine and nutraceuticals.

"It's still difficult for doctors and other alternative health practitioners to prescribe smoking as a form of medicine. Jeff and his team have been in the pharma manufacturing industry for decades and have been doing research in cannabis for years collecting a wealth of experience and knowledge that even most big pharma companies don't have."

Canntab and FSD Pharma intend to execute a definitive agreement by July 15 this year.

]]>
Tue, 10 Jul 2018 09:00:00 -0400 https://www.proactiveinvestors.com/companies/news/200490/canntab-therapeutics-unveils-collaboration-with-fsd-pharma-ahead-of-canada-s-nationwide-legalization-200490.html
<![CDATA[News - Canntab Therapeutics launches first cannabis wellness products: a Hemp oil capsule ]]> https://www.proactiveinvestors.com/companies/news/199252/canntab-therapeutics-launches-first-cannabis-wellness-products-a-hemp-oil-capsule-199252.html Canntab Therapeutics Ltd (CSE:PILL) has met another milestone, as it launched the first of its '420 Therapeutics' brand of Cannabis wellness products - Hemp oil gel capsules.

Each capsule contains 50 milligrams (mg) of purified hemp seed oil extracted from cannabis sativa and suspended in coconut oil. Hemp oil is supposed to have health benefits.

"We are excited to announce the launch of Hemp Oil Gel Capsules, which are the first in our innovative line of 420 Therapeutics products," said Jeffrey Renwick, chief executive at Canntab.

"We intend to release additional exciting formulations that combine natural, hemp-based cannabidiol with a range of healthy ingredients.

"This is only the first step in realizing Canntab's goal of becoming a leading provider of cannabis oral dosage formulations."

Antioxidants

Ingredients within the capsules have been linked to the following benefits: Antioxidants are said to help protect the body's cells and shield it from the oxidative damage caused by free radicals.

Coconut oil contains Lauric acid that is proven to be effective at killing bacteria, fungi and certain viruses, while capric acid and medium triglycerides help increase the body's energy expenditure for weight control and also help to build  muscle.

"All of our 420 Therapeutics products will use state of the art tamper-proof blister packaging, which allows us to avoid the leakage that often occurs when capsules are kept in large bottles, since the capsules kept in bottles frequently bounce off one another and become damaged," said Richard Goldstein, finance chief at Canntab.

"Our packaging keeps the underlying product intact, and provides for discretionary and safe consumption of one capsule at a time."

420 Therapeutics Inc is a wholly-owned subsidiary of Canntab created to meet the growing desire for adult use cannabis products that are of high quality, but without the negative effects associated with smoking marijuana.

Canntab Therapeutics shares added 3.23% C$0.64 in Toronto.

]]>
Wed, 20 Jun 2018 10:34:00 -0400 https://www.proactiveinvestors.com/companies/news/199252/canntab-therapeutics-launches-first-cannabis-wellness-products-a-hemp-oil-capsule-199252.html
<![CDATA[News - Canntab Therapeutics merging medical cannabis with pharmaceutical expertise ]]> https://www.proactiveinvestors.com/companies/news/198122/canntab-therapeutics-merging-medical-cannabis-with-pharmaceutical-expertise-198122.html The cannabis market is full of potential and creativity, with companies introducing new and innovative products every day. Dispensaries have gone way beyond smokable marijuana, offering customers everything from cannabis-infused edibles like beer and chocolate to personal care products like lotion and eye creams.

But the cannabis market isn’t all fun and games. Canntab Therapeutics Ltd. (CSE:PILL) is looking to fill a need in the pharmaceutical space.

Based in Ontario, the company was founded by pharmaceutical industry professionals. Chief Executive Officer Jeff Renwick was the former CEO of Orbus Pharma Inc., a generic drug developer and manufacturer. Prior to that, he was at Indukern Chemie AG, a Swiss pharmaceutical company.

Although once a private company, Canntab merged with Telferscot Resources on April 20, 2017 — a date synonymous with marijuana. Exactly one year later, the company went public on the unofficial pot holiday.

READ: Canntab Therapeutics files two Canadian patent applications

The company is presumably the first to offer medical marijuana in pill form.

The technology behind the pill was licensed from a predecessor firm. Since then, Canntab has filed seven patents for its two products. Approval from Health Canada to proceed with third-party clinical trials is in the works.

When a patient smokes marijuana or eats cannabis-infused edibles, it can be difficult to measure exactly how much of the medicinal elements are being delivered.

Chief Financial Officer Richard Goldstein also points to the potential danger of cannabis products being created by those without a pharmaceutical background, without GMP, or “Good Manufacturing Practices,” in place.

“A lot of it is being made in home kitchens and home basements. They’re not being made in the GMP environment. And yet, the marketplace continues to eat this stuff up. It’s quite scary at a level,” says Goldstein. He recalled a story where the tablets were so poorly pressed that they weren’t able to be dissolved in a patient’s system before exiting.

In contrast, the company’s extended-release tablets offer a consistent, stable dose each time and aren’t susceptible to spoiling and converting into other cannabinoid elements when exposed to certain environments like an oil-filled gel capsule would be.

“In true pharma, the only time you use a capsule to deliver medication is when you can’t have a tablet for that medication. If you can have a tablet, that is always the first choice,” says Renwick.

The tablets are intended to treat a variety of disorders, including Post-Traumatic Stress Disorder and arthritis. They can also act as a pain management and appetite loss drug for patients undergoing cancer treatments.

The pill delivery mechanism may also be the first step in reducing the stigma of marijuana by removing the smoking aspect.

Renwick recently had a conversation with a landlord who was spending hours in court after tenants complained about neighbors smoking marijuana, some of whom were using it for legal, medicinal purposes. The pill can be a smokeless alternative in areas where smoking isn’t allowed.

READ: Canntab Therapeutics bolsters advisory board with pharmaceutical executive

Canntab believes the pill alternative will also appeal to senior citizens who take multiple pills per day, especially in assisted living facilities where smoking may not be allowed.

“They’re not going to smoke. They’re not going to eat gummy bears, but they’ll take a pill if it makes them sleep better,” says Renwick.

The company does have a sleeping pill in the works, although clinical trials will still need to be performed.

And a future product line may include cannabis tablets intended to specifically treat sleep and social anxiety disorders.

While the legal landscape is always evolving from place to place, the company has come to agreements to expand outside of Canada.

Canntab is working on import and export permits, with agreements already in place to send tablets to Australia and Germany. Deals with Poland, Spain, and Greece are also being discussed.

Moving into the U.S. market is challenging. Recreational marijuana use is already legal in nine states, including California, Washington, Oregon and Nevada. Medicinal marijuana is legal in a total of 29 states, including those West Coast states as well as East Coast states like New York and Delaware. But on the federal level, cannabis is still illegal.

“Ultimately, we want to get something going in the US, preferably in California,” says Renwick.

The company has said it has a “soft plan” to get there by perhaps 2019. A lawyer is looking into licensing in California on its behalf.

A 2017 Gallup poll found that 64% of Americans support the legalization of marijuana.

Looking to the future, Canntab’s CFO is confident that the company is in good financial shape.

Goldstein notes that the company’s immediate cash needs have been fulfilled after going public.

“The good news is that we have lots of money to do what we want to do in the short term and then as opportunities present themselves, we’ll seek capital if necessary,” says Goldstein.

]]>
Fri, 01 Jun 2018 11:29:00 -0400 https://www.proactiveinvestors.com/companies/news/198122/canntab-therapeutics-merging-medical-cannabis-with-pharmaceutical-expertise-198122.html
<![CDATA[News - Canntab Therapeutics files two Canadian patent applications ]]> https://www.proactiveinvestors.com/companies/news/197738/canntab-therapeutics-files-two-canadian-patent-applications-197738.html Canntab Therapeutics Ltd (CSE:PILL) announced today that it recently filed two additional Canadian patent applications, bolstering its intellectual property portfolio. Canntab's portfolio now includes 13 applications in Canada, the US and internationally.

The company, which offers medical marijuana in pill form, said the new applications were related to oral formulations of pharmaceutical cannabis, including sustained release cannabinoid formulations and sustained release cannabinoid pellets. Canntab is the first company to offer medical marijuana in pill form in Canada and possibly the rest of the world.

READ: Canntab Therapeutics unveils major milestone, with Canada Health approval for its sustained release product

The new patent applications extend Canntab’s intellectual property portfolio, which includes patent applications and trademark applications in the United States and Canada.

Canntab is currently developing a number of products, which include an extended-release tablet that contains a mixture of THC (tetrahydrocannabinol) and CBD (cannabidiol) that may be helpful in the treatment of a number of ailments.

These include: sleep disorders, post-traumatic stress disorder (PTSD), social anxiety, addiction, arthritis, general pain, pain management and appetite loss associated with cancer treatments, and addiction treatment therapy of opioids and other painkillers.

WATCH: Canntab Therapeutics debuts shares on 'serendipitous' 4/20

Most conventional dosing forms release the active drug immediately after taking it orally. In sustained release forms, the active ingredient is released at a steady rate, which maintains a constant concentration over a time period. Canntab’s product is designed to release the cannaboid content over a period of at least 12 hours.

The company is currently in the process of seeking approval from Health Canada on its extended release tablets and is making batches of the tablets for third-party clinical trials in Canada. Canntab also plans to enter the US market by obtaining a manufacturing and distributors license in certain US states.

Shares were up 1.11% at C$0.91 on Friday.

]]>
Fri, 25 May 2018 11:59:00 -0400 https://www.proactiveinvestors.com/companies/news/197738/canntab-therapeutics-files-two-canadian-patent-applications-197738.html
<![CDATA[News - Canntab Therapeutics bolsters advisory board with pharmaceutical executive ]]> https://www.proactiveinvestors.com/companies/news/197225/canntab-therapeutics-bolsters-advisory-board-with-pharmaceutical-executive-197225.html Canntab Therapeutics (CSE:PILL) announced it has appointed pharmaceutical executive Bob Woloschuk to its advisory board.

Bob has more than two decades of executive experience in the pharmaceutical industry and an eye for licensing opportunities, both in Canada and in international markets, the firm said.

READ: Canntab Therapeutics unveils major milestone, with Canada Health approval for its sustained release product

"We are grateful for the opportunity to add someone of Bob's calibre to our advisory board, which already included some of the most impressive names in both capital markets, and cannabis research and development,” said chief executive officer, Jeff Renwick, who is also a director.

Canntab’s advisory board is also made up of researcher Sabrina Ramkellawan, cannabis leader Hamish Sutherland and medical doctor, Dr. Eric Hatashita.

“Bob has a long history of successful business development within the key "Big Pharma" industry players, and has significant experience developing licensing strategies in the pharmaceutical industry,” said Renwick. “We look forward to working with Bob, who we believe adds tremendous value to our advisory board and the company as a whole.”

Shares in Canntab were down 0.92% to C$1.08 on Friday morning. 

]]>
Thu, 17 May 2018 14:36:00 -0400 https://www.proactiveinvestors.com/companies/news/197225/canntab-therapeutics-bolsters-advisory-board-with-pharmaceutical-executive-197225.html
<![CDATA[News - Canntab Therapeutics unveils major milestone, with Canada Health approval for its sustained release product ]]> https://www.proactiveinvestors.com/companies/news/196934/canntab-therapeutics-unveils-major-milestone-with-canada-health-approval-for-its-sustained-release-product-196934.html Canntab Therapeutics Ltd (CSE:PILL) has unveiled a major milestone -  as the firm along with partner Emblem Corp (CVE:EMC) have received Health Canada approval for research and development activities on oral sustained release formulations of Canntab's cannabinoids product, sending shares higher.

Canntab has brought equipment to Emblem’s Ontario location and will begin making the first pivotal batch of the product this week, using its patented technology and proprietary processes.

READ: Canntab Therapeutics extends its intellectual property portfolio

The pair struck a collaboration and licensing deal in October last year related to development, regulatory approval, manufacturing, and commercialisation of Canntab’s patent-pending sustained release product.

“The extended release tablet is the perfect pharmaceutical dosage form," said Jeffrey Renwick, chief executive at Canntab.

"It’s a game changer for the medical community and solves many problems for patients.

"We are excited to be working with Emblem to bring this innovative product to market."

Evidence suggests that cannabinoids are effective for treating a number of conditions, including chronic pain, nausea, sleep disorders, and for symptoms of multiple sclerosis.

Designed to release cannabinoid content over at least 12 hours

Most conventional dosage forms release the active drug immediately after oral administration.

But in sustained release forms, the active pharmaceutical ingredient is released at a predetermined rate in order to maintain a constant drug concentration over a specific period of time – resulting in a longer duration of action from a single dose and often with reduced side effects.

Canntab’s product is designed to release the cannabinoid content over a period of at least 12 hours, which is particularly valuable in the treatment of chronic pain conditions.

Emblem chief Nick Dean said: "We believe that cannabis medications need to be in precise, dose-controlled formats supported by pharmacokinetic, dosing and clinical data to be most consistent, effective, and broadly accepted by prescribers and their patients."

Shares in Canntab added over 7% to C$0.90.

]]>
Mon, 14 May 2018 09:29:00 -0400 https://www.proactiveinvestors.com/companies/news/196934/canntab-therapeutics-unveils-major-milestone-with-canada-health-approval-for-its-sustained-release-product-196934.html
<![CDATA[News - Canntab Therapeutics extends its intellectual property portfolio ]]> https://www.proactiveinvestors.com/companies/news/196333/canntab-therapeutics-extends-its-intellectual-property-portfolio-196333.html Canntab Therapeutics Ltd (CNSX:PILL) has now filed 11 patents related to pharmaceutical cannabis.

These filings, which include seven non-provisional United States patent applications and four patent co-operation treaty (PCT) patent applications, build on Canntab's growing intellectual property portfolio.

READ Pot pill maker Canntab Therapeutics debuts on Canadian exchange, shares pop​

These patent applications are part of Canntab's concerted strategy to develop a comprehensive intellectual property portfolio that covers the company's technology and formulations related to pharmaceutical preparations that contain natural or synthetic cannabinoids.

Canntab is currently developing a number of products that use this technology, which includes a variety of extended released tablets containing a mixture of THC (tetrahydrocannabinol) and CBD (cannabidiol) that can be used to treat a number of ailments, such as sleep disorders, post-traumatic stress disorder (PTSD), social anxiety, addiction, arthritis, general pain, and the pain management and appetite loss associated with cancer treatments.

The company is currently awaiting a decision from Health Canada on its extended release tablets and is making batches of the tablets for third party clinical trials in Canada.


 

]]>
Thu, 26 Apr 2018 14:54:00 -0400 https://www.proactiveinvestors.com/companies/news/196333/canntab-therapeutics-extends-its-intellectual-property-portfolio-196333.html
<![CDATA[News - Canntab Therapeutics eyes Australian market with joint venture agreement ]]> https://www.proactiveinvestors.com/companies/news/196338/canntab-therapeutics-eyes-australian-market-with-joint-venture-agreement-196338.html Canntab Therapeutics Ltd (CNSX:PILL) has engaged a consultant to advise on its application for a dealer licence in Canada.

Trevor Moore, a veteran of the Canadian medical cannabis industry, has been retained by the company to assist in preparing its application to obtain a Health Canada dealer licence under the Controlled Drugs and Substances Act (CDSA) and its associated regulations.

READ Pot pill maker Canntab Therapeutics debuts on Canadian exchange, shares pop​

Moore has previously helped two licensed producers obtain their licences and is an expert in the areas of quality assurance, regulatory compliance and government relations.

Securing a dealer's licence will allow Canntab to continue with the development of its proprietary products, including the extended-release tablet (XR tablet), and will allow Canntab to manufacture and sell the products in Canada and elsewhere.

Canntab also announced it has entered into a joint venture (JV) agreement with Queensland Bauxite that will see the JV manufacture, distribute and sell Canntab's proprietary products, including its XR cannabis tablets, in Australia. The joint venture may extend to other territories in Asia, Canntab revealed.

Vitacan, a wholly-owned subsidiary of Queensland Bauxite, has agreed to contribute the first US$1mln of capital required by the joint venture.

"We are very excited to expand Canntab's business to the Australian market, which is a very progressive market for the development and sale of marijuana and marijuana products," said Jeffrey Renwick, the chief executive officer of Canntab.

]]>
Tue, 24 Apr 2018 15:23:00 -0400 https://www.proactiveinvestors.com/companies/news/196338/canntab-therapeutics-eyes-australian-market-with-joint-venture-agreement-196338.html
<![CDATA[Media files - Canntab Therapeutics debuts shares on 'serendipitous' 4/20 ]]> https://www.proactiveinvestors.com/companies/stocktube/9122/canntab-therapeutics-debuts-shares-on-serendipitous-420-9122.html Fri, 20 Apr 2018 09:00:00 -0400 https://www.proactiveinvestors.com/companies/stocktube/9122/canntab-therapeutics-debuts-shares-on-serendipitous-420-9122.html <![CDATA[News - Pot pill maker Canntab Therapeutics debuts on Canadian exchange, shares pop ]]> https://www.proactiveinvestors.com/companies/news/195408/pot-pill-maker-canntab-therapeutics-debuts-on-canadian-exchange-shares-pop-195408.html Canntab Therapeutics Ltd (CSE:PILL) shares started trading on the Canadian Securities Exchange on Friday, offering traders another way to play the cannabis industry on the most significant day of the year for marijuana enthusiasts.

The company offers medical marijuana in pill form — the first to do so in Canada, and possibly the rest of the world — the reason being that a pot pill would be easier to digest and better for the health of those who have trouble smoking.

Shares popped past C$1 in early trading.

The company is headed by CEO Jeff Renwick with Chief Financial Officer Richard Goldstein. Barry M. Polisuk, Sheldon Inwentash and Vitor Fonseca are directors.

A significant day to debut

The once-private group was founded April 20, 2016, by pharmaceutical industry professionals and comes to the public market after merging with shell resource group Telferscot Resources.

April 20 is celebrated by pot aficionados worldwide based on its shorthand date of 4/20, which in turn is derived from the time of day a group of 1970s California high school kids who called themselves the "Waldos" would meet to light up after school.

READ: Callitas Health looks to line up partners for its cannabis-related products

Canntab licensed its technology from a predecessor firm, which had spent about C$2mln developing two extended-release tablets — one of which has received a patent.  The company has to date filed seven patents for its two products and entered agreements with Emblem Cannabis Corp, which has a licensed producer's license.

Plans for the next eight months include obtaining approval from Health Canada for the tablets and making batches for third-party clinical trials in Canada.

READ: Scotts to buy Sunlight Supply for US$450mln to expand sales to cannabis growers

The company also aims to expand into some US states where it will seek a manufacturing and distributors license.

"We are proud to announce that Canntab has joined the growing family of cannabis companies listed on the CSE, and believe that this represents an important milestone for the company and our loyal shareholders," said Renwick. "Canntab was able to take this step on only the second anniversary from its date of incorporation, and we intend to continue taking steps like these to enhance shareholder value, increase liquidity and execute on our strategic vision."

]]>
Thu, 19 Apr 2018 15:42:00 -0400 https://www.proactiveinvestors.com/companies/news/195408/pot-pill-maker-canntab-therapeutics-debuts-on-canadian-exchange-shares-pop-195408.html